Beam Therapeutics Inc.
BEAM Nasdaq
SEC CIK 1745999
Follow Beam Therapeutics
Weekly email: filings, results
Revenue, last quarter
$307K
−96.8% vs same quarter last year
Net income
−$134.4M
−19.4% vs same quarter last year
EPS, diluted
−$1.28
−16.4% vs same quarter last year
Operating cash flow
−$110.7M
−35.9% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $139.7M | −$80M |
| FY24 | $63.5M | −$376.7M |
| FY23 | $377.7M | −$132.5M |
| FY22 | $60.9M | −$289.1M |
| FY21 | $51.8M | −$370.7M |
| FY20 | $24K | −$194.6M |
| FY19 | $18K | −$78.3M |
| FY18 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −274.6% | −57.2% |
| FY24 | −654.3% | −593.1% |
| FY23 | −46.7% | −35.1% |
| FY22 | −555.6% | −474.5% |
| FY21 | −757% | −715% |
| FY20 | −553166.7% | −810800% |
| FY19 | −417522.2% | −435144.4% |
| FY18 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$360M |
| FY24 | −$356.2M |
| FY23 | −$182.9M |
| FY22 | −$26.4M |
| FY21 | −$113.1M |
| FY20 | −$112.1M |
| FY19 | −$84.5M |
| FY18 | - |
- Beam Therapeutics
- Healthcare median
Show the numbers
| Year | Beam Therapeutics | Healthcare median |
|---|---|---|
| FY25 | −57.2% | −30.6% |
| FY24 | −593.1% | −47% |
| FY23 | −35.1% | −58% |
| FY22 | −474.5% | −80.4% |
| FY21 | −715% | −71.8% |
| FY20 | −810800% | −62.2% |
| FY19 | −435144.4% | −46.2% |
| FY18 | - | −49.6% |